Cargando…

Transmission and re-infection of Omicron variant XBB.1.5 in hamsters

BACKGROUND: Like its predecessors in the XBB family, XBB.1.5 is highly immune evasive from therapeutic monoclonal antibodies and neutralizing antibodies generated by vaccination and/or infection. However, there is a lack of in vivo data on XBB.1.5 in animal models such as Syrian hamsters. METHODS: S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Halfmann, Peter J., Uraki, Ryuta, Kuroda, Makoto, Iwatsuki-Horimoto, Kiyoko, Yamayoshi, Seiya, Ito, Mutsumi, Kawaoka, Yoshihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329098/ https://www.ncbi.nlm.nih.gov/pubmed/37352827 http://dx.doi.org/10.1016/j.ebiom.2023.104677

Ejemplares similares

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
por: Imai, Masaki, et al.
Publicado: (2022)

Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate
por: Uraki, Ryuta, et al.
Publicado: (2023)

Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB
por: Uraki, Ryuta, et al.
Publicado: (2023)

Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate
por: Uraki, Ryuta, et al.
Publicado: (2023)

Evaluation of the fusion partner cell line SPYMEG for obtaining human monoclonal antibodies against influenza B virus
por: SONI, Priyanka, et al.
Publicado: (2018)

Previous omicron infection may be protective against reinfection with omicron variant BA.5 for at least 5 months
por: Koga, Michiko, et al.
Publicado: (2023)

Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75
por: Takashita, Emi, et al.
Publicado: (2022)

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
por: Takashita, Emi, et al.
Publicado: (2022)

Subclade 2.2.1-Specific Human Monoclonal Antibodies That Recognize an Epitope in Antigenic Site A of Influenza A(H5) Virus HA Detected between 2015 and 2018
por: Okuda, Moe, et al.
Publicado: (2019)

Diversity of antigenic mutants of influenza A(H1N1)pdm09 virus escaped from human monoclonal antibodies
por: Yasuhara, Atsuhiro, et al.
Publicado: (2017)

Recurring and Adaptable Binding Motifs in Broadly Neutralizing Antibodies to Influenza Virus Are Encoded on the D3-9 Segment of the Ig Gene
por: Wu, Nicholas C., et al.
Publicado: (2018)

In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6
por: Takashita, Emi, et al.
Publicado: (2022)

Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates
por: Uraki, Ryuta, et al.
Publicado: (2023)

Gargle Lavage as a Safe and Sensitive Alternative to Swab Samples to Diagnose COVID-19: A Case Report in Japan
por: Saito, Makoto, et al.
Publicado: (2020)

Antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination
por: Ishizaka, Aya, et al.
Publicado: (2023)

Seroprevalence of SARS-CoV-2 antibodies in dogs and cats during the early and mid-pandemic periods in Japan
por: Yamayoshi, Seiya, et al.
Publicado: (2023)

Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant
por: Takashita, Emi, et al.
Publicado: (2022)

SARS-CoV-2 Transmission from Virus-Infected Dead Hamsters
por: Iwatsuki-Horimoto, Kiyoko, et al.
Publicado: (2023)

Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1
por: Uraki, Ryuta, et al.
Publicado: (2023)

Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model
por: Chiba, Shiho, et al.
Publicado: (2022)

In SARS-CoV-2 delta variants, Spike-P681R and D950N promote membrane fusion, Spike-P681R enhances spike cleavage, but neither substitution affects pathogenicity in hamsters
por: Furusawa, Yuri, et al.
Publicado: (2023)

Efficacy of antivirals and mRNA vaccination against an XBF clinical isolate
por: Uraki, Ryuta, et al.
Publicado: (2023)

A Broadly Reactive Human Anti-hemagglutinin Stem Monoclonal Antibody That Inhibits Influenza A Virus Particle Release
por: Yamayoshi, Seiya, et al.
Publicado: (2017)

In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir
por: Kiso, Maki, et al.
Publicado: (2023)

Antibody-Dependent Enhancement of SARS-CoV-2 Infection Is Mediated by the IgG Receptors FcγRIIA and FcγRIIIA but Does Not Contribute to Aberrant Cytokine Production by Macrophages
por: Maemura, Tadashi, et al.
Publicado: (2021)

Efficacy of vaccination and previous infection against the Omicron BA.1 variant in Syrian hamsters
por: Halfmann, Peter J., et al.
Publicado: (2022)

Development of an Influenza Rapid Diagnostic Kit Specific for the H7 Subtype
por: Iwatsuki-Horimoto, Kiyoko, et al.
Publicado: (2018)

Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development
por: Imai, Masaki, et al.
Publicado: (2020)

What to know about Omicron XBB.1.5
por: Vogel, Lauren
Publicado: (2023)

Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2
por: Kawaoka, Yoshihiro, et al.
Publicado: (2022)

Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters
por: Takamatsu, Yuki, et al.
Publicado: (2022)

A Novel Method to Reduce ELISA Serial Dilution Assay Workload Applied to SARS-CoV-2 and Seasonal HCoVs
por: Pattinson, David, et al.
Publicado: (2022)

SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters
por: Halfmann, Peter J., et al.
Publicado: (2022)

Emergence and geographic dominance of Omicron subvariants XBB/XBB.1.5 and BF.7 – the public health challenges
por: Velavan, Thirumalaisamy P., et al.
Publicado: (2023)

Comparative Sensitivity of Rapid Antigen Tests for the Delta Variant (B.1.617.2) of SARS-CoV-2
por: Sakai-Tagawa, Yuko, et al.
Publicado: (2021)

The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters
por: Diamond, Michael, et al.
Publicado: (2021)

In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir
por: Kiso, Maki, et al.
Publicado: (2023)

Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant
por: Uriu, Keiya, et al.
Publicado: (2023)

Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model
por: Driouich, Jean-Sélim, et al.
Publicado: (2023)

Enhanced Replication of Highly Pathogenic Influenza A(H7N9) Virus in Humans
por: Yamayoshi, Seiya, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kd5dj6lin11mtqm7nkk9otn5ek